Viltolarsen (NS-065/NCNP-01)

Exon 53 Skipping for DMD

Leslie Magnus, MD
Vice President, Medical Affairs
NS Pharma, Inc.

June 29, 2019
Forward-Looking Statements

- Forward-Looking Statements NS Pharma presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward looking statements. For additional information, including important risk factors, please refer to the company website.

- This presentation may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts or words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible," "goal," "strategy," "may," "should," "project," "estimate," and similar expressions are intended to identify forward-looking statements."
NS Pharma and Nippon Shinyaku

**NS Pharma, Inc.** (Paramus, NJ, USA)
- Wholly-owned, US subsidiary of Nippon Shinyaku Co., Ltd (Kyoto, Japan)
- Sponsor of the North American Phase 2 trials
- Focus area: Orphan Rare Disease

**Nippon Shinyaku** (Kyoto, Japan)
- Parent company of NS Pharma, Inc.
- Founded in 1919
- Four focus areas are: drugs for rare diseases, urological diseases, hematology, and gynecology.
Overview: How Protein is Made

Step 1: Make the message

Step 2: Trim the message

Step 3: Make the protein

Step 4: Utilize the protein
Exon Skipping Strategy

Example of a deletion that disrupts the dystrophin mRNA reading frame that is restored to in-frame by exon 53 skipping

Exon 48-52 deletion: disrupts reading frame

Exon 53 skipping by viltolarsen (NS-065/NCNP-01): restores reading frame

viltolarsen (NS-065/NCNP-01)
Exon Skipping Overview

Step 1: Make the message
Step 2: Trim the message
Step 3: Make the protein
Step 4: Utilize the protein
Viltolarsen (NS-065/NCNP-01)

Origin
Nippon Shinyaku jointly with National Center of Neurology and Psychiatry (NCNP)

Mechanism
Exon 53 skipping

Characteristics
- Antisense oligonucleotide with a morpholino backbone and a neutral charge
- Demonstrated exon 53 skipping activity
- Demonstrated dystrophin production across multiple models
- I.V. administration, once weekly
Viltolarsen (NS-065/NCNP-01)
Clinical Program

**Phase I/II**
Dose finding study (NORTH AMERICA)
40, 80mg/kg for 24 weeks

**Phase II**
Extension study (NORTH AMERICA)
40, 80mg/kg, ongoing

NS Pharma, Inc.

Nippon Shinyaku
jointly with
National Center of Neurology
and Psychiatry (NCNP)

**Phase I**
Investigator Initiated study (JAPAN)
1.25, 5, 20 mg/kg for 12 weeks

**Phase I/II**
Dose finding study (JAPAN)
40, 80 mg/kg for 24 weeks
Phase 3 study

• Most phase 3 clinical trials have a larger number of patients and longer than phase 1 and 2 studies.
• We are planning to start Phase 3 study in 3Q/4Q, 2019. Details will be found in [www.clinicaltrials.gov](http://www.clinicaltrials.gov) in the future.
Viltolarsen (NS-065/NCNP-01) Community Announcement

NS Pharma Community Letter

Dear Friends,

NS Pharma is pleased to announce that we have initiated submission of a rolling New Drug Application (NDA) seeking accelerated approval for viltolarsen (NS-065/NCNP-01), an investigational drug for the treatment of Duchenne Muscular Dystrophy (DMD) in patients amenable to exon 53 skipping. While this is the first step towards the US regulatory approval, we wanted to share our news with the DMD community.

As you may know, NS Pharma has completed a Phase 2 study in North America, and its parent company, Nippon Shinyaku Co., Ltd. (Headquarters, Kyoto, Japan; President, Shigenobu Maekawa) completed a Phase 1/2 study in Japan. The scientists, investigators, and families all made great efforts to collect data about the safety and efficacy of viltolarsen (NS-065/NCNP-01) in clinical trials. Viltolarsen (NS-065/NCNP-01) is not approved in any country for use outside clinical trials.

Working together to analyze the data, we have decided to move forward to seek regulatory approval. We have submitted the first portion of the data and reports to the US Food and Drug Administration (FDA) under rolling review pathway. Under that pathway, the sponsor is allowed to start submission with completed portions of the application for review by FDA rather than waiting until every portion is completed. NS Pharma plans to complete the NDA submission in September 2019.

Finally, we would like to take this moment to thank all the researchers, clinical trial staff, and families around the world who have made this step possible. We deeply appreciate everyone’s hard work and dedication, and thank you for your continued support.

Thank you,
Tsugio Tanaka
President, NS Pharma, Inc.

For family or community questions: Email dmdresearch@nspharma.com
To learn more about viltolarsen (NS-065/NCNP-01): Please visit www.nspharma.com

- Initiation of rolling NDA submission for viltolarsen was done by Nippon Shinyaku to the FDA.

- NS Pharma and Nippon Shinyaku plan to complete the NDA submission in September of 2019.

- It has been granted Rare Pediatric Disease Designation, Orphan Drug Designation, Fast Track Designation, and Accelerated Approval process.
# DMD Pipeline

<table>
<thead>
<tr>
<th></th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Clinical</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>viltolarsen</strong></td>
<td></td>
<td></td>
<td>P2(US)</td>
</tr>
<tr>
<td>(NS-065/NCNP-01)</td>
<td></td>
<td></td>
<td>P1/2(JPN)</td>
</tr>
<tr>
<td>(Exon 53 Skipping)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Exon</strong></td>
<td></td>
<td>Preclinical</td>
<td></td>
</tr>
<tr>
<td><strong>Skipping Programs</strong></td>
<td></td>
<td>Discovery</td>
<td></td>
</tr>
</tbody>
</table>
Acknowledgement

North American Phase II study

Site Investigators
- Vamshi Rao, Lurie Children’s Hospital, Chicago, IL
- Anne Connolly, Washington University, St. Louis, MO
- Amy Harper, Children’s Hospital of Richmond, Richmond, VA
- Jean Mah, Alberta Children’s Hospital, Calgary, Alberta, Canada
- Edward Smith, Duke Children’s Hospital, Durham, NC
- Craig McDonald, University of California, Davis, Sacramento, CA
- Barry Byrne, University of Florida, Gainesville, FL

AGADA Biosciences
Eric Hoffman

TRiNDS
Lauren Morgenroth

PharmaLex

Japan Phase I/II Study

Site Investigators
- Yasuhiro Takeshima, Hyogo College of Medicine
- Tsuyoshi Matsumura, Toneyama National Hospital
- Shiro Ozasa, Kumamoto University Hospital
- Michinori Funato, Nagara Medical Center
- Hiroyumi Komaki, National Center of Neurology and Psychiatry (NCNP)

Medical Advisor
Shin’ichi Takeda, National Center of Neurology and Psychiatry (NCNP)

Sponsor: Nippon Shinyaku Co., Ltd.

Thank you to all the patients and families who made these studies possible!